Perspective Therapeutics (CATX) EBITDA Margin (2010 - 2023)

Perspective Therapeutics has disclosed EBITDA Margin across 14 years of filings, most recently posting 238.19% for Q4 2023.

• In Q4 2023, EBITDA Margin changed N/A year-over-year to 238.19%; the TTM figure through Dec 2023 stood at 2855.02% (changed N/A YoY), while the FY2023 annual figure was 2855.02%, changed N/A from the prior year.
• EBITDA Margin came in at 238.19% for Q4 2023 at Perspective Therapeutics, up from 446.22% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 238.19% in Q4 2023 to a low of 473.15% in Q1 2023.
• Average EBITDA Margin over 5 years is 101.02%, with a median of 52.17% recorded in 2020.
• Year-over-year, EBITDA Margin jumped 8839 bps in 2019 and plunged 42586 bps in 2023.
• Over 5 years, EBITDA Margin stood at 40.93% in 2019, then gained by 10 bps to 37.01% in 2020, then slumped by 57 bps to 58.06% in 2021, then sank by 86 bps to 107.82% in 2022, then jumped by 321 bps to 238.19% in 2023.
• Per Business Quant data, the three most recent EBITDA Margin figures were 238.19% in Q4 2023, 446.22% in Q3 2023, and 467.15% in Q2 2023.